SLT Laser for Glaucoma: A Boca Raton Guide

If you have been told you have glaucoma or ocular hypertension, you have probably also been handed a prescription for eye drops and the expectation that you will use them every day for the rest of your life. For a long time, that was simply how glaucoma was treated. What many patients in Boca Raton do not realize is that this default has changed. A laser procedure called selective laser trabeculoplasty, or SLT, is now considered a reasonable first-line treatment for many people with open-angle glaucoma, not just a fallback when drops fail. This shift is backed by a large clinical trial and reflected in the official treatment guidelines from the American Academy of Ophthalmology.

This guide explains what SLT does, why the evidence moved it to the front of the line, how it compares to drops, who is a good candidate, and what the procedure and recovery are really like. It is written for an educated patient and is not a substitute for a glaucoma evaluation with a board-certified ophthalmologist. Glaucoma is a leading cause of irreversible blindness, and South Florida's older population means we have this conversation in our glaucoma program in Boca Raton nearly every day.

What Is Selective Laser Trabeculoplasty?

Selective laser trabeculoplasty is a brief, in-office laser procedure that lowers the pressure inside the eye. It does not involve any cutting, no incision is made, and nothing is implanted. Instead, a specialized laser delivers low-energy pulses of light to the eye's natural drainage tissue to help fluid leave the eye more efficiently. The result, in most patients who respond, is a meaningful drop in intraocular pressure, which is the single most important modifiable risk factor in glaucoma.

How SLT lowers eye pressure

The eye constantly produces a clear fluid called aqueous humor that nourishes the front of the eye and then drains away. In open-angle glaucoma, this fluid does not drain as well as it should, and pressure builds up over time. That elevated pressure gradually damages the optic nerve, which is what causes the slow, painless loss of peripheral vision that defines the disease.

SLT works on the drainage system itself. The laser stimulates a biological response in the drainage tissue that improves outflow, so fluid leaves the eye more easily and the pressure comes down. Importantly, the word "selective" is meaningful here. The laser targets only specific pigmented cells and leaves the surrounding tissue intact, which is why SLT can be repeated and why it carries a low risk of structural damage to the drainage angle. According to the American Academy of Ophthalmology, this selectivity is part of what makes SLT a gentle, repeatable option.

What the laser is targeting (the trabecular meshwork)

The drainage tissue SLT treats is called the trabecular meshwork. It is a delicate, sponge-like ring of tissue that sits in the angle where the iris meets the cornea, and it is the main route through which aqueous humor exits the eye. In open-angle glaucoma, the angle is open and looks anatomically normal, but the meshwork itself is not draining efficiently.

During SLT, the laser energy is applied to this meshwork. The treated tissue responds by recruiting the body's own cellular cleanup processes, which appear to restore some of the meshwork's drainage function. Because the laser is low energy and selective, it does not scar or burn the meshwork the way older laser techniques could, which is why SLT can often be performed more than once over a patient's lifetime.

Why SLT Is Now Considered First-Line for Many Patients

For decades, the standard approach was to start nearly every glaucoma patient on daily eye drops and reserve laser or surgery for cases where drops were not enough. SLT existed, but it was usually offered later. Two developments changed the conversation: a large, well-designed clinical trial and an update to the official treatment guidelines.

The LiGHT trial in plain English

The LiGHT trial, published in The Lancet in 2019, was a landmark study that directly compared starting treatment with SLT versus starting treatment with eye drops in patients newly diagnosed with open-angle glaucoma or ocular hypertension. Patients were randomly assigned to one approach or the other and then followed for years.

The results, reported by Gazzard and colleagues, were striking. At three years, a large majority of eyes treated first with SLT were at their target pressure without needing any drops at all. The SLT group also had fewer patients requiring glaucoma surgery, and disease control was at least as good as the drops group. In plain terms, starting with the laser allowed many people to control their glaucoma without the daily burden, cost, and side effects of drops. This is the evidence that moved SLT to the front of the line.

The 2022 AAO Preferred Practice Pattern update

Clinical guidelines are how the profession translates evidence like the LiGHT trial into everyday practice. The American Academy of Ophthalmology publishes a document called the Preferred Practice Pattern for primary open-angle glaucoma, and its updated guidance now recognizes SLT as an appropriate initial therapy, not merely a second-line option. The AAO Preferred Practice Pattern reflects the same direction the LiGHT data pointed: for many patients with open-angle glaucoma or ocular hypertension, offering SLT as a first treatment is a reasonable, evidence-based choice. That is why your ophthalmologist may now raise laser as an option at your very first visit, rather than after years of drops.

SLT vs Glaucoma Eye Drops: A Side-by-Side Comparison

Neither SLT nor drops is universally "better." Each has strengths, and the right choice depends on your eye, your pressure, your other medical conditions, and your lifestyle. Here is how the two approaches compare across the factors that matter most.

Pressure lowering

Both SLT and a typical first-line prostaglandin eye drop produce a similar magnitude of pressure lowering in patients who respond. In the LiGHT trial, the level of pressure control achieved by starting with SLT was comparable to starting with drops, and disease progression rates were at least as good in the laser group. The key qualifier is candidacy: SLT works best in open-angle glaucoma and ocular hypertension, and not every eye responds. Your ophthalmologist measures your response at follow-up.

Adherence and cost

This is where SLT has a real practical advantage for many people. Eye drops only work if they are used correctly every single day, and adherence is famously difficult. Drops can be expensive over time, bottles run out, travel complicates the routine, and many older patients struggle to aim a drop into the eye or to remember a daily schedule. SLT removes that daily burden entirely for as long as the effect lasts. For patients tired of drops, struggling with the monthly cost, or finding it hard to keep up with the regimen, this is often the deciding factor.

Side effects

Glaucoma drops can cause red eyes, stinging, darkening or growth of the lashes, changes in iris color, and, in some classes, effects on heart rate or breathing. These are usually manageable but are present every day the drop is used. SLT, by contrast, has very few side effects. Most patients experience nothing more than mild, short-lived inflammation or a temporary pressure fluctuation in the first day or so. There is no daily medication exposure, which is part of the appeal. We will cover the specific risks in the safety section below.

Durability and repeatability

An eye drop works only as long as you keep using it. SLT provides a sustained effect, but it is not permanent. The pressure-lowering benefit of SLT typically lasts a few years and then may gradually wear off. The advantage is that SLT can usually be repeated, which is one of its defining features. A drop, once stopped, loses its effect immediately. SLT, once it fades, can often be performed again to restore pressure control. We discuss timelines in detail further down.

Who Is a Good Candidate for SLT?

SLT is not right for every type of glaucoma or every patient. Candidacy is determined by a comprehensive glaucoma evaluation, including a careful look at the drainage angle.

Open-angle glaucoma and ocular hypertension

The best candidates for SLT are patients with open-angle glaucoma or ocular hypertension, the same populations studied in the LiGHT trial. In these conditions, the drainage angle is open, the trabecular meshwork is accessible to the laser, and the evidence for SLT as a first or early treatment is strongest. Newly diagnosed patients weighing all their options, and patients who would prefer to avoid daily drops, are often ideal candidates.

When SLT may not be the right first step

SLT is generally not appropriate for certain forms of glaucoma, including angle-closure glaucoma, where the drainage angle is anatomically narrow or closed, and some types of secondary or advanced glaucoma. Patients with very high baseline pressures or significant optic nerve damage may need a more aggressive approach from the start. Inflammatory (uveitic) glaucoma is another situation where SLT is usually avoided. Pregnancy is a setting where treatment choices are individualized, and SLT may actually be attractive precisely because it avoids systemic drop exposure, but this is a decision to make directly with your ophthalmologist. The point is that the drainage angle must be evaluated before SLT is offered.

SLT after years on drops

SLT is not only for the newly diagnosed. Many patients who have been on drops for years are excellent candidates. SLT can be added to reduce the number of daily drops a patient needs, or used to regain control when drops alone are no longer holding the pressure low enough. It can also be a welcome option for long-time patients who have grown tired of the daily routine, the cost, or the surface irritation that years of drops can cause. If you have been on glaucoma drops for a long time, it is worth asking whether SLT could simplify your regimen. You can read more about the glaucoma eye drops we prescribe and how laser fits alongside them.

What the SLT Procedure Is Like

One of the reasons patients respond well to SLT is that the experience is far less involved than the word "laser surgery" suggests. It is an outpatient procedure performed right in the office.

Before the appointment

SLT requires very little preparation. You can eat normally and take your usual medications. Because the procedure does not require general anesthesia or sedation, you are awake and comfortable throughout. Some patients arrange a ride home simply for convenience, since your vision may be briefly blurry afterward, but many drive themselves. Your ophthalmologist may instruct you to continue your current glaucoma drops up to and sometimes through the procedure, depending on your situation.

The 5 to 10 minute laser session

The treatment itself is quick. A numbing drop is placed in the eye so you feel little to nothing. A special contact lens is then gently placed on the surface of the eye to focus the laser precisely on the trabecular meshwork. The ophthalmologist delivers a series of laser pulses around the drainage angle. The active laser portion typically takes only about five to ten minutes per eye. The lens is then removed, and you are done.

What you feel and see

Most patients describe SLT as painless or close to it. You may see flashes of light during the laser pulses and feel a light pressure from the lens on the eye, but the procedure does not hurt the way patients often fear. Afterward, vision may be slightly blurry or the eye may feel mildly gritty for a short time. These sensations are normal and brief. There is no patch and no need to keep the eye covered.

Recovery and What to Expect After SLT

Recovery from SLT is one of its biggest advantages over incisional glaucoma surgery. There is essentially no downtime.

The first 24 hours

In the first day after SLT, it is normal to have mild redness, a scratchy sensation, or slight light sensitivity. Some patients are prescribed a short course of anti-inflammatory drops; others are not, depending on the ophthalmologist's preference and your eye's response. You can generally return to your normal activities the same day, including reading, screen use, and light exercise. Significant pain, marked vision loss, or a red, painful eye is not expected and should prompt a same-day call to our office.

When pressure starts to drop

SLT does not lower pressure instantly. The biological response in the trabecular meshwork takes time to develop. Most patients see the pressure begin to come down over the following weeks, with the full effect typically established by one to three months. For that reason, your ophthalmologist will not judge whether the treatment worked on the day of the procedure. You may be asked to continue your current drops until the SLT effect is confirmed, then taper them under supervision if appropriate.

Follow-up schedule at West Boca Eye Center

After SLT, we typically check the eye pressure shortly after the procedure to make sure there is no early pressure spike, then again over the following weeks and months to measure the treatment's effect. Once your pressure is stable at target, you return to a regular glaucoma monitoring schedule with pressure checks, optic nerve evaluation, and visual field testing as appropriate. Ongoing monitoring never stops in glaucoma, because the disease is lifelong even when it is well controlled. For patients whose pressure is not adequately controlled by SLT or drops, we discuss the next steps, including when surgery is needed.

How Long Does SLT Last and Can It Be Repeated?

The pressure-lowering effect of SLT is durable but not permanent. In most patients who respond, the benefit lasts on the order of one to several years, and in some it lasts longer. Over time, the effect can gradually fade, and the pressure may begin to creep back up.

The good news, and one of SLT's defining strengths, is that it can usually be repeated. If the effect wears off, a repeat SLT can often be performed to restore pressure control, frequently with a similar response to the first treatment. This repeatability is a direct consequence of the laser's selectivity: because it does not scar the trabecular meshwork, the tissue can be treated again. This stands in contrast to older laser techniques, which were limited in how often they could be applied. For patients, this means SLT is not a one-time gamble but a tool that can be used more than once across the course of the disease.

Cost and Medicare Coverage for SLT

For many of our Boca Raton patients, who are often on Medicare, cost is a meaningful part of the decision. SLT is an established, FDA-cleared procedure for open-angle glaucoma, and it is generally a covered benefit under Medicare and most insurance plans when performed for a recognized indication. This is different from elective procedures that are paid for out of pocket.

It is also worth weighing the long-term economics against drops. Daily glaucoma medications represent a recurring cost that continues for life, and that cost adds up substantially over the years. SLT, by contrast, is a one-time procedure that may reduce or eliminate the need for drops for a period of time. We always recommend confirming your specific coverage and any out-of-pocket responsibility with your insurer, since plans vary, but for most patients SLT is financially accessible. Our team can help you understand the coverage picture before you proceed.

SLT at West Boca Eye Center

At West Boca Eye Center, SLT is a core part of our approach to glaucoma. We evaluate every glaucoma patient individually, examine the drainage angle, review your pressure history and optic nerve, and discuss whether starting with the laser, starting with drops, or combining approaches makes the most sense for you. We are guided by the evidence, including the LiGHT trial and the AAO Preferred Practice Pattern, and by your own preferences about daily drops, cost, and convenience.

In our Boca Raton practice, we frequently offer SLT to newly diagnosed open-angle glaucoma patients who would rather not begin a lifelong daily drop regimen, and to long-standing patients looking to simplify or strengthen their treatment. Candidacy for SLT is determined by a comprehensive glaucoma evaluation. For patients who ultimately need more than laser, we also offer the full range of glaucoma care, including medications, glaucoma drainage implants, and surgical options, all under one roof. You can learn more about the ophthalmologist leading your care on Dr. Bellotte's bio page.

Important Safety Information

This article is for general education and is not medical advice. The decision to treat glaucoma with SLT, eye drops, or surgery must be individualized by a qualified ophthalmologist after a comprehensive evaluation that includes examination of the drainage angle. SLT is generally well tolerated, but like any procedure it carries risks. These include, but are not limited to, a temporary rise in intraocular pressure in the hours after treatment, short-term inflammation inside the eye, mild discomfort, blurred vision, light sensitivity, and headache. Less commonly, the pressure-lowering effect may be insufficient or may not last, in which case additional treatment is needed. SLT is not appropriate for all forms of glaucoma, including angle-closure and certain secondary or inflammatory glaucomas. SLT is not a cure for glaucoma; it is one tool for controlling intraocular pressure, and lifelong monitoring remains essential because glaucoma damage is irreversible. Any significant pain, marked vision loss, or a red and painful eye after SLT requires prompt evaluation. SLT should not be described as universally superior to eye drops; the better option depends on individual candidacy.

Frequently Asked Questions

Is SLT better than glaucoma eye drops?

Neither is universally better. For many patients with open-angle glaucoma or ocular hypertension, the LiGHT trial showed that starting with SLT controls pressure at least as well as starting with drops, while sparing the daily burden, cost, and side effects of medication. But not every eye responds to SLT, and some forms of glaucoma are not suitable for it. The right choice depends on your individual candidacy, which is determined by a comprehensive glaucoma evaluation.

Does SLT hurt?

Most patients describe SLT as painless or nearly so. A numbing drop is used, and a contact lens focuses the laser. You may see flashes of light and feel mild pressure from the lens, but the procedure itself does not typically cause pain. Afterward, the eye may feel slightly gritty or look mildly red for a short time.

How long does SLT take?

The active laser portion usually takes only about five to ten minutes per eye. Including check-in, numbing, and a brief observation period afterward, you should expect to be in the office longer than that, but the treatment itself is quick and done the same day with no incision.

How soon will my eye pressure go down after SLT?

SLT does not lower pressure immediately. The effect develops gradually over the following weeks, and the full benefit is typically established within one to three months. Your ophthalmologist will measure your pressure at follow-up visits before deciding whether and how to adjust your drops.

How long does SLT last, and can it be repeated?

In patients who respond, the effect typically lasts on the order of one to several years, and sometimes longer. When the effect fades, SLT can usually be repeated, often with a similar response. This repeatability is one of the procedure's main advantages and is possible because the laser does not scar the drainage tissue.

Is SLT covered by Medicare?

SLT is an FDA-cleared procedure for open-angle glaucoma and is generally a covered benefit under Medicare and most insurance plans when performed for a recognized indication. Coverage and out-of-pocket costs vary by plan, so we recommend confirming the specifics with your insurer. Over time, SLT may also reduce the recurring cost of daily drops.

Can SLT replace my drops completely?

Sometimes. In the LiGHT trial, many patients treated first with SLT were able to control their glaucoma without any drops for a period of time. Whether you can stop drops entirely depends on how well your pressure responds, and any change to your medication is made under your ophthalmologist's supervision, not on your own.

Schedule a Glaucoma Evaluation in Boca Raton

West Boca Eye Center serves patients from Boca Raton, Delray Beach, Boynton Beach, Deerfield Beach, Parkland, and Coral Springs. If you have been diagnosed with open-angle glaucoma or ocular hypertension, are tired of daily drops, or simply want to understand all of your options, an in-office evaluation is the right next step. Call our office this week to schedule a glaucoma evaluation, or request an appointment through our contact page to find out whether SLT is a good fit for your eyes.